查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1957266

精準診斷市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、最終用途、地區和競爭對手分類，2021-2031年

Precision Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End-Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球精準診斷市場預計將從 2025 年的 165.1 億美元大幅成長至 2031 年的 304.2 億美元，複合年成長率為 10.72%。

在該領域，基因測序、生物標記鑑定和分子分析被用於精確定義疾病，從而為個別患者制定個人化治療策略。推動市場擴張的關鍵因素包括複雜慢性疾病負擔的日益加重以及高通量定序技術成本的持續下降。這些因素共同推動了對精準分子譜分析的需求，而精準分子譜分析對於最大程度地提高臨床療效和減少藥物不良反應至關重要。

市場概覽
預測期 2027-2031
市場規模：2025年 165.1億美元
市場規模：2031年 304.2億美元
複合年成長率：2026-2031年 10.72%
成長最快的細分市場 臨床檢查室
最大的市場 北美洲

然而，该行业面临着诸多挑战，特别是构建先进检测平台所需的大量资本投入以及报销途径的不確定性。這兩點都可能限制患者獲得治療的機會。個人化醫療聯盟強調了這些診斷工具日益融入臨床實踐的重要性。該聯盟在2024年的報告中指出，個人化醫療約占美國食品藥物管理局（FDA）前一年核准的所有新治療分子實體的38%。這項數據凸顯了建構完善的診斷基礎設施以支持標靶治療有效實施的迫切需求。

市場促進因素

癌症和罕見遺傳疾病發生率的上升是全球精準診斷市場的主要驅動力。隨著這些複雜疾病發生率的增加，醫療系統被迫採用基因測序和分子分析來檢測用於標靶治療的特定生物標記。大量新增病例需要进行精准的基因分析，这凸显了精准诊断的紧迫性。例如，美國癌症協會於2024年1月發布的《2024年癌症事實與數據》報告預測，美國新增癌症病例數將首次超過200萬例。面對如此龐大的患者數量，建立健全的診斷框架至關重要，以確保治療方法能夠根據疾病的個別基因特徵量身定做，並最大限度地減少無效治療。

同時，將人工智慧 (AI) 整合到診斷分析中對於解讀複雜的基因組數據至關重要。 AI 演算法可以分析定序產生的大量資料集，從而提高偵測速度和準確性。 2024 年 8 月 Fierce Medtech 的報告《FDA 批准的 AI醫療設備清單擴展至 950 件》指出，監管機構已核准了950 件支持 AI 和機器學習的醫療設備，這標誌著該領域監管工作的進展。該領域的經濟規模進一步凸顯了這些先進解決方案的普及應用。 Exact Sciences 的案例便是一個例證，該公司在 2023 年 12 月的財報中宣布，其 2024 會計年度的收入將達到 25 億美元，這反映出精準篩檢平台的巨大價值。

市場挑戰

開發複雜檢測平台所需的大量資本投入以及不確定的報銷環境是全球精準診斷市場成長的主要障礙。開發和檢驗高通量基因組檢測方法需要大量的前期投資，但這些投資的回收往往受到支付方政策不一致和報銷率下降的威脅。當診斷開發商無法獲得穩定的收入來源時，他們就不太願意籌集必要的研發資金來推出新的分子檢測方法。因此，產業的創新周期停滯不前，先進診斷工具的普及也受到限制。

這種財務不穩定直接阻礙了市場擴張，迫使實驗室縮減檢測項目或推遲新檢測方法的商業化，以確保流動性。 2024年，美國臨床實驗室協會（ACLA）報告稱，現行的聯邦定價法規將導致約800項常用檢測服務在2025年初面臨高達15%的報銷削減。這種持續的支付水準下行壓力造成了不永續的經濟環境，使醫療機構難以維持為廣大患者群體提供精準、數據驅動的診斷服務所需的先進基礎設施。

市場趨勢

液態生物檢體技術的進步正從根本上改變市場格局，實現了非侵入性腫瘤分析和即時監測。與傳統的切片檢查不同，基於血液的檢測方法使臨床醫生能夠動態評估微量殘存疾病（MRD）和治療反應。醫療機構正迅速採用這項技術，利用循環腫瘤DNA比影像學檢查更早發現復發。 Netara于2025年2月发布的2024年第四季度及全年财报清晰地展现了这一趋势。報告顯示，該公司在2024年進行了約528,200例腫瘤檢測，較去年同期成長54.9%。這顯示液體分子檢測在腫瘤治療領域的應用取得了顯著進展。

同時，精準診斷技術向神經系統領域的多元化發展正在推動市場成長，尤其是在阿茲海默症管理方面。隨著新治療方法的出現，人們越來越需要更方便的篩檢工具來取代侵入性的腦脊髓液分析和高成本的PET掃描。基於血液的生物標記，例如pTau-217，在這一轉變過程中發揮關鍵作用，為識別澱粉樣蛋白病理提供了可擴展的方法。 2025年4月，《MedTech Dive》雜誌發表了一篇題為「Labcorp推出血液檢測以加速阿茲海默症診斷」的報導，證實了這一進展。報導中，Labcorp宣布其pTau-217確診檢測的敏感度和特異度均達到了95%。向神經系統適應症的拓展顯著拓寬了市場範圍，使其不再局限於傳統的以腫瘤學為中心的框架。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球精準診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（基因檢測、直接消費者檢測、專業檢測、其他）
    • 依應用領域（腫瘤學、呼吸系統疾病、皮膚病、中樞神經系統疾病、免疫學、遺傳性疾病等）
    • エンドユーザー別（病院、臨床檢查室、その他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美精準診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲先進診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區精準診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲精準診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲精準診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球精準診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • bioMerieux SA
  • Becton, Dickinson and Company
  • Danaher Corporation
  • QIAGEN NV
  • Hologic Inc.
  • Agilent Technologies Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24133

The Global Precision Diagnostics Market is projected to experience substantial growth, rising from USD 16.51 Billion in 2025 to USD 30.42 Billion by 2031, representing a CAGR of 10.72%. This sector employs genomic sequencing, biomarker identification, and molecular analysis to define diseases with granular specificity, thereby allowing for customized therapeutic strategies for individual patients. Key drivers propelling this market expansion include the escalating burden of complex chronic diseases and the steady decrease in costs related to high-throughput sequencing technologies. Together, these factors drive the demand for accurate molecular profiling, which is essential for maximizing clinical results and reducing adverse drug reactions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 16.51 Billion
Market Size 2031USD 30.42 Billion
CAGR 2026-203110.72%
Fastest Growing SegmentClinical Laboratories
Largest MarketNorth America

However, the industry faces significant obstacles, notably the high capital investment needed to build sophisticated testing platforms and the uncertainty surrounding reimbursement pathways, both of which can restrict patient access. The increasing integration of these diagnostic tools into clinical practice is highlighted by the Personalized Medicine Coalition, which reported in 2024 that personalized medicines comprised approximately 38 percent of all new therapeutic molecular entities approved by the Food and Drug Administration the previous year. This statistic emphasizes the critical need for precise diagnostic infrastructure to support the effective deployment of targeted therapies.

Market Driver

The rising prevalence of oncology and rare genetic disorders acts as a major catalyst for the Global Precision Diagnostics Market. As the incidence of these complex conditions increases, healthcare systems are compelled to adopt genomic sequencing and molecular analysis to detect specific biomarkers for targeted treatment. This urgency is underscored by the sheer volume of new diagnoses requiring precise profiling; for instance, the American Cancer Society's "Cancer Facts & Figures 2024" report from January 2024 projected that new cancer cases in the United States would exceed 2 million for the first time. Such growing patient numbers necessitate robust diagnostic frameworks to ensure therapies are aligned with the individual genetic characteristics of a disease, thereby minimizing ineffective treatments.

Simultaneously, the incorporation of artificial intelligence into diagnostic analytics is becoming essential for interpreting intricate genomic data. AI algorithms are capable of analyzing the massive datasets produced by sequencing, enhancing both detection speed and accuracy. Regulatory progress in this area was noted in an August 2024 Fierce Medtech report titled "FDA's list of authorized AI medical devices grows to 950," which indicated that regulators had cleared 950 AI and machine learning-enabled medical devices. The financial magnitude of this sector further confirms the adoption of these advanced solutions, as evidenced by Exact Sciences, which reported 2024 revenues of $2.50 billion for the fiscal year ending December 2023, reflecting the substantial value attributed to precision screening platforms.

Market Challenge

The significant capital expenditure required to develop complex testing platforms, along with uncertain reimbursement landscapes, presents a major barrier to the growth of the Global Precision Diagnostics Market. Creating and validating high-throughput genomic assays entails substantial upfront costs, yet the return on this investment is often threatened by inconsistent payer policies and declining fee schedules. When diagnostic developers cannot rely on stable revenue streams, they are less likely to fund the research needed to introduce novel molecular tests, which in turn stalls the industry's innovation cycle and limits the availability of advanced diagnostic tools.

This financial instability directly impedes market expansion by forcing laboratories to scale back their test menus or postpone the commercialization of new assays to conserve liquidity. In 2024, the American Clinical Laboratory Association reported that approximately 800 frequently ordered laboratory services were facing scheduled reimbursement cuts of up to 15 percent by early 2025 due to current federal rate-setting regulations. Such persistent downward pressure on payment rates creates an unsustainable economic environment, making it difficult for providers to maintain the sophisticated infrastructure required to deliver precise, data-driven diagnostic care to the broader patient population.

Market Trends

The advancement of liquid biopsy capabilities is fundamentally transforming the market by facilitating non-invasive tumor profiling and real-time monitoring. Unlike traditional tissue biopsies, blood-based assays enable clinicians to dynamically assess Minimal Residual Disease (MRD) and treatment response. This technology is being rapidly adopted as providers leverage circulating tumor DNA to detect recurrence earlier than imaging allows. This trend is exemplified by Natera's February 2025 report on its "Fourth Quarter and Full Year 2024 Financial Results," which noted the company performed roughly 528,200 oncology tests in 2024, a 54.9 percent increase from the prior year, illustrating the significant shift toward incorporating fluid-based molecular testing into oncological care.

Concurrently, the diversification of precision diagnostics into neurology is driving market growth, particularly regarding Alzheimer's disease management. With the emergence of new therapies, there is a need for accessible screening tools to replace invasive cerebrospinal fluid analysis and costly PET scans. Blood-based biomarkers such as pTau-217 are central to this transition, offering a scalable method for identifying amyloid pathology. This progress was confirmed in an April 2025 MedTech Dive article titled "Labcorp launches blood test to accelerate Alzheimer's diagnosis," where Labcorp announced that its confirmatory pTau-217 test achieved 95 percent sensitivity and specificity. Expanding into neurological indications significantly broadens the market scope beyond its traditional focus on oncology.

Key Market Players

  • Abbott Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • bioMerieux SA
  • Becton, Dickinson and Company
  • Danaher Corporation
  • QIAGEN N.V.
  • Hologic Inc.
  • Agilent Technologies Inc

Report Scope

In this report, the Global Precision Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Precision Diagnostics Market, By Type

  • Genetic Tests
  • Direct to Consumer Tests
  • Esoteric Tests
  • Others

Precision Diagnostics Market, By Application

  • Oncology
  • Respiratory Diseases
  • Skin Diseases
  • CNS Disorders
  • Immunology
  • Genetic Diseases
  • Others

Precision Diagnostics Market, By End-Use

  • Hospitals
  • Clinical Laboratories
  • Others

Precision Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Precision Diagnostics Market.

Available Customizations:

Global Precision Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Precision Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Genetic Tests, Direct to Consumer Tests, Esoteric Tests, Others)
    • 5.2.2. By Application (Oncology, Respiratory Diseases, Skin Diseases, CNS Disorders, Immunology, Genetic Diseases, Others)
    • 5.2.3. By End-Use (Hospitals, Clinical Laboratories, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Precision Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End-Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Precision Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-Use
    • 6.3.2. Canada Precision Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-Use
    • 6.3.3. Mexico Precision Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-Use

7. Europe Precision Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End-Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Precision Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-Use
    • 7.3.2. France Precision Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-Use
    • 7.3.3. United Kingdom Precision Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-Use
    • 7.3.4. Italy Precision Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-Use
    • 7.3.5. Spain Precision Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-Use

8. Asia Pacific Precision Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End-Use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Precision Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-Use
    • 8.3.2. India Precision Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-Use
    • 8.3.3. Japan Precision Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-Use
    • 8.3.4. South Korea Precision Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-Use
    • 8.3.5. Australia Precision Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-Use

9. Middle East & Africa Precision Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End-Use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Precision Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-Use
    • 9.3.2. UAE Precision Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-Use
    • 9.3.3. South Africa Precision Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-Use

10. South America Precision Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End-Use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Precision Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-Use
    • 10.3.2. Colombia Precision Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-Use
    • 10.3.3. Argentina Precision Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Precision Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd.
  • 15.3. Siemens Healthineers AG
  • 15.4. Thermo Fisher Scientific Inc.
  • 15.5. bioMerieux SA
  • 15.6. Becton, Dickinson and Company
  • 15.7. Danaher Corporation
  • 15.8. QIAGEN N.V.
  • 15.9. Hologic Inc.
  • 15.10. Agilent Technologies Inc

16. Strategic Recommendations

17. About Us & Disclaimer